Colchicine: Difference between revisions

Jump to navigation Jump to search
Newer edit →
VisualWikitext
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Protected "Colchicine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))
 
Vignesh Ponnusamy (talk | contribs)
nocaptcha
7,606 edits
No edit summary
Line 1: Line 1:
{{Drugbox|
{{DrugProjectFormSinglePage
|IUPAC_name = N-((7S)-5,6,7,9-tetrahydro-<BR>1,2,3,10-tetramethoxy-9-<BR>oxobenzo(a)heptalen-7-yl)-<BR>acetamide
|authorTag=
| image=Colchicine structure.png
 
| CAS_number=64-86-8
{{VP}}
| ATC_prefix=M04
 
| ATC_suffix=AC01
<!--Overview-->
| ATC_supplemental=
 
| PubChem=6167
|genericName=
| DrugBank=
 
| C=22 | H=25 | N=1 | O=6
Colchicine
| molecular_weight = 399.437
 
| bioavailability=  
|aOrAn=
| metabolism =  
 
| elimination_half-life=
an
| excretion =
 
| pregnancy_category = X
|drugClass=
| legal_status = RX/POM
 
| routes_of_administration= Oral tablets
alkaloid
}}
 
'''Colchicine''' is a highly poisonous [[natural product]] and [[secondary metabolite]], originally extracted from plants of the genus ''[[Colchicum]]'' ([[Autumn crocus]], also known as the "Meadow saffron"). Originally used to treat rheumatic complaints and especially [[gout]], it was also prescribed for its [[cathartic]] and [[emetic]] effects. Its present medicinal use is mainly in the treatment of gout; as well, it is being investigated for its potential use as an anti-[[cancer]] drug. It can also be used as initial treatment for [[pericarditis]] and preventing recurrences of the condition.
|indication=
 
gout flares in adults, familial mediterranean fever (FMF) in adults and children 4 years or older
 
|hasBlackBoxWarning=
 
|adverseReactions=
 
 
 
<!--Black Box Warning-->
 
|blackBoxWarningTitle=
Title
 
|blackBoxWarningBody=
<i><span style="color:#FF0000;">ConditionName: </span></i>
 
* Content
 
<!--Adult Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Adult)-->
 
|fdaLIADAdult=
 
=====Gout Flares=====
 
* Dosing Information
 
*Prophylaxis of Gout Flares:
:*The recommended dosage of COLCRYS for prophylaxis of gout flares for adults and adolescents older than 16 years of age is 0.6 mg once or twice daily. The maximum recommended dose for prophylaxis of gout flares is 1.2 mg/day.
 
*Treatment of Gout Flares:
:*The recommended dose of COLCRYS for treatment of a gout flare is 1.2 mg (2 tablets) at the first sign of the flare followed by 0.6 mg (1 tablet) one hour later. Higher doses have not been found to be more effective. The maximum recommended dose for treatment of gout flares is 1.8 mg over a 1 hour period. COLCRYS may be administered for treatment of a gout flare during prophylaxis at doses not to exceed 1.2 mg (2 tablets) at the first sign of the flare followed by 0.6 mg (1 tablet) one hour later. Wait 12 hours and then resume the prophylactic dose.
 
=====Familial Mediterranean fever (FMF)=====
 
* Dosing Information
 
:*The recommended dosage of COLCRYS for FMF in adults is 1.2 mg to 2.4 mg daily.
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
 
|offLabelAdultGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
 
|offLabelAdultNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
 
|fdaLIADPed=
 
=====Familial Mediterranean fever (FMF)=====
 
* Dosing Information
 
:* The recommended dosage of COLCRYS for FMF in pediatric patients 4 years of age and older is based on age. The following daily doses may be given as a single or divided dose twice daily:
:**Children 4 – 6 years: 0.3 mg to 1.8 mg daily
:**Children 6 – 12 years: 0.9 mg to 1.8 mg daily
:**Adolescents older than 12 years: 1.2 mg to 2.4 mg daily
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
 
|offLabelPedGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
 
|offLabelPedNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
 
|contraindications=
 
*Patients with renal or hepatic impairment should not be given COLCRYS in conjunction with P-gp or strong CYP3A4 inhibitors (this includes all protease inhibitors, except fosamprenavir). In these patients, life-threatening and fatal colchicine toxicity has been reported with colchicine taken in therapeutic doses.
 
<!--Warnings-->
 
|warnings=
 
* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
 
|clinicalTrials=
 
There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
 
|postmarketing=
 
There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
 
|drugInteractions=
 
* Drug
:* Description
 
<!--Use in Specific Populations-->
 
|useInPregnancyFDA=
* '''Pregnancy Category'''
 
|useInPregnancyAUS=
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 
|useInLaborDelivery=
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
 
|useInNursing=
There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
 
|useInPed=
There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
 
|useInGeri=
There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 
|useInGender=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
|useInRace=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
 
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
 
|useInReproPotential=
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
 
|administration=
 
* Oral
 
* Intravenous
 
|monitoring=
 
There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description
 
<!--IV Compatibility-->
 
|IVCompat=
 
There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
 
|overdose=
 
===Acute Overdose===
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
 
|drugBox=
 
 
 
<!--Mechanism of Action-->
 
|mechAction=
 
*
 
<!--Structure-->
 
|structure=
 
*
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
 
|PD=
 
There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
 
|PK=
 
There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
 
|nonClinToxic=
 
There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
 
|clinicalStudies=
 
There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
<!--How Supplied-->
 
|howSupplied=
 
*
 
<!--Patient Counseling Information-->


== History ==
|fdaPatientInfo=


Colchicum extract was first described as a treatment for gout in ''De Materia Medica'' by [[Dioscorides|Padanius Dioscorides]] in the first century [[Common Era|CE]].
There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.


The colchicine alkaloid was first isolated in [[1820]] by the two French chemists P.S. Pelletier and J. Caventon.<ref>Pelletier PS, Caventon J. Ann. Chim. Phys. 1820;14:69</ref>
<!--Precautions with Alcohol-->


It was later identified as a tricyclic alkaloid, and its pain-relieving and anti-inflammatory effects for gout were linked to its ability to bind with [[tubulin]].
|alcohol=


== Pharmacology ==
* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
===Biological function===
Colchicine inhibits microtubule polymerization by binding to [[tubulin]], one of the main constituents of [[microtubule]]s. Availability of tubulin is essential to [[mitosis]], and therefore colchicine effectively functions as a "mitotic poison" or [[spindle poison]].<ref>http://biotech.icmb.utexas.edu/botany/colch.html</ref> Since one of the defining characteristics of cancer cells is a significantly increased rate of mitosis, this means that cancer cells are significantly more vulnerable to colchicine poisoning than are normal cells. However, the therapeutic value of colchicine against cancer is (as is typical with [[chemotherapy]] agents) limited by its toxicity against normal cells.


Apart from inhibiting mitosis, a process heavily dependent on cytoskeletal changes, colchicine also inhibits [[neutrophil granulocyte|neutrophil]] motility and activity, leading to a net [[inflammation|anti-inflammatory]] effect.
<!--Brand Names-->


===Colchicine as medicine===
|brandNames=
Colchicine is [[Food and Drug Administration]] (FDA)-approved for the treatment of [[gout]] and also for [[familial Mediterranean fever]], secondary [[amyloidosis]](AA), and [[scleroderma]].


The Australian biotechnology company [[Giaconda]] has developed a combination therapy to treat constipation-predominant [[irritable bowel syndrome]] which combines colchicine with the anti-inflammatory drug [[olsalazine]].
* ®<ref>{{Cite web | title =  | url =  }}</ref>


Colchicine has a relatively low [[therapeutic index]].
<!--Look-Alike Drug Names-->


Colchicine is "used widely" [[off-label]] by [[naturopath]]s for a number of treatments, including the treatment of back pain.<ref>[http://www.portlandtribune.com/news/story.php?story_id=117701511863232000 "Deaths sound an Rx alert"], ''The Portland Tribune'', Apr 20, 2007</ref>
|lookAlike=


===Side effects===
* A® — B®<ref name="www.ismp.org">{{Cite web  | last = | first = | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
Side effects include gastro-intestinal upset and [[neutropenia]]. High doses can also damage [[bone marrow]] and lead to [[anaemia]]. Note that all of these side effects can result from hyper-inhibition of mitosis.


===Toxicity===
<!--Drug Shortage Status-->
Colchicine poisoning has been compared to [[arsenic]] poisoning: symptoms start 2 to 5 hours after the toxic dose has been ingested and include burning in the mouth and throat, [[fever]], [[vomiting]], [[diarrhoea]], [[abdominal pain]] and [[renal failure|kidney failure]]. Death from respiratory failure can follow. There is no specific antidote for colchicine, although various treatments do exist.


===Botanical use===
|drugShortage=
Since [[chromosome segregation]] is driven by microtubules, colchicine is also used for inducing [[polyploid]]y in plant cells during [[cellular division]] by inhibiting [[chromosome]] segregation during [[meiosis]]; half the resulting [[gamete]]s therefore contain no chromosomes, while the other half contain double the usual number of chromosomes (''i.e.'', [[diploid]] instead of [[haploid]] as gametes usually are), and lead to embryos with double the usual number of chromosomes (''i.e.'' [[tetraploid]] instead of diploid). While this would be fatal in animal cells, in plant cells it is not only usually well tolerated, but in fact frequently results in plants which are larger, hardier, faster growing, and in general more desirable than the normally diploid parents; for this reason, this type of genetic manipulation is frequently used in breeding plants commercially. In addition, when such a tetraploid plant is crossed with a diploid plant, the [[triploid]] offspring will be sterile (which may be commercially useful in itself by requiring growers to buy seed from the supplier) but can often be induced to create a "seedless" fruit if pollinated (usually the triploid will also not produce pollen, therefore a diploid parent is needed to provide the pollen). This is the method used to create seedless [[watermelon]]s, for instance.  On the other hand, colchicine's ability to induce polyploidy can be exploited to render infertile hybrids fertile, as is done when breeding [[triticale]] from [[wheat]] and [[rye]].  Wheat is typically tetraploid and rye diploid, with the triploid hybrid infertile.  Treatment with colchicine of triploid triticale gives fertile [[hexaploid]] triticale.
}}


When used to induce [[polyploidy]] in plants, colchicine is usually applied to the plant as a cream.  It has to be applied to a growth point of the plant, such as an apical tip, shoot or sucker.  Seeds can be presoaked in a colchicine solution before planting.  As colchicine is so dangerous, it is worth noting that doubling of chromosome numbers can occur spontaneously in nature, and not infrequently.  The best place to look is in regenerating tissue.  One way to induce it is to chop off the tops of plants and carefully examine the lateral shoots and suckers to see if any look different.  <ref>Deppe, Carol (1993). ''Breed Your own Vegetable Varieties''.  Little, Brown & Company. p.150-151. ISBN 0-316-18104-8</ref>
<!--Pill Image-->


==References==
{{PillImage
<references/>
|fileName=No image.jpg|This image is provided by the National Library of Medicine.
|drugName=
|NDC=
|drugAuthor=
|ingredients=
|pillImprint=
|dosageValue=
|dosageUnit=
|pillColor=
|pillShape=
|pillSize=
|pillScore=
}}


==External links==
<!--Label Display Image-->
*[http://www.phc.vcu.edu/Feature/oldfeature/colchicine/colchicine.html Feature] on colchicine, by Matthew J. Dowd at vcu.edu


{{LabelImage
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}
{{LabelImage
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}


{{Antigout preparations}}
<!--Category-->
[[Category:Alkaloids]]
[[Category:Antigout agents]]


[[cs:Kolchicin]]
[[Category:Drug]]
[[de:Colchicin]]
[[es:Colchicina]]
[[fr:Colchicine]]
[[gl:Colquicina]]
[[id:Kolkisin]]
[[it:Colchicina]]
[[nl:Colchicine]]
[[ja:コルヒチン]]
[[pl:Kolchicyna]]
[[pt:Colchicina]]
[[wa:Coltchicene]]
[[zh:秋水仙素]]
[[sr:колхицин]]
{{WikiDoc Help Menu}}

Revision as of 19:40, 10 September 2014

Colchicine
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vignesh Ponnusamy, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Colchicine is an alkaloid that is FDA approved for the {{{indicationType}}} of gout flares in adults, familial mediterranean fever (FMF) in adults and children 4 years or older. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Gout Flares
  • Dosing Information
  • Prophylaxis of Gout Flares:
  • The recommended dosage of COLCRYS for prophylaxis of gout flares for adults and adolescents older than 16 years of age is 0.6 mg once or twice daily. The maximum recommended dose for prophylaxis of gout flares is 1.2 mg/day.
  • Treatment of Gout Flares:
  • The recommended dose of COLCRYS for treatment of a gout flare is 1.2 mg (2 tablets) at the first sign of the flare followed by 0.6 mg (1 tablet) one hour later. Higher doses have not been found to be more effective. The maximum recommended dose for treatment of gout flares is 1.8 mg over a 1 hour period. COLCRYS may be administered for treatment of a gout flare during prophylaxis at doses not to exceed 1.2 mg (2 tablets) at the first sign of the flare followed by 0.6 mg (1 tablet) one hour later. Wait 12 hours and then resume the prophylactic dose.
Familial Mediterranean fever (FMF)
  • Dosing Information
  • The recommended dosage of COLCRYS for FMF in adults is 1.2 mg to 2.4 mg daily.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Colchicine in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Colchicine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Familial Mediterranean fever (FMF)
  • Dosing Information
  • The recommended dosage of COLCRYS for FMF in pediatric patients 4 years of age and older is based on age. The following daily doses may be given as a single or divided dose twice daily:
    • Children 4 – 6 years: 0.3 mg to 1.8 mg daily
    • Children 6 – 12 years: 0.9 mg to 1.8 mg daily
    • Adolescents older than 12 years: 1.2 mg to 2.4 mg daily

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Colchicine in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Colchicine in pediatric patients.

Contraindications

  • Patients with renal or hepatic impairment should not be given COLCRYS in conjunction with P-gp or strong CYP3A4 inhibitors (this includes all protease inhibitors, except fosamprenavir). In these patients, life-threatening and fatal colchicine toxicity has been reported with colchicine taken in therapeutic doses.

Warnings

  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Colchicine in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Colchicine in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Colchicine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Colchicine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Colchicine with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Colchicine with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Colchicine with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Colchicine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Colchicine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Colchicine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Colchicine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Colchicine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Colchicine in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Colchicine in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Colchicine in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Colchicine in the drug label.

Pharmacology

There is limited information regarding Colchicine Pharmacology in the drug label.

Mechanism of Action

Structure

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Colchicine in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Colchicine in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Colchicine in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Colchicine in the drug label.

How Supplied

Storage

There is limited information regarding Colchicine Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Colchicine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Colchicine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Colchicine in the drug label.

Precautions with Alcohol

  • Alcohol-Colchicine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Empty citation (help)
  2. ↑ "http://www.ismp.org". External link in |title= (help)


{{#subobject: 

 |Page Name=Colchicine
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}


{{#subobject: 

 |Label Page=Colchicine
 |Label Name=Colchicine11.png

}}


{{#subobject: 

 |Label Page=Colchicine
 |Label Name=Colchicine11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Colchicine&oldid=1020199"